Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient

Minh N. Pham; Matthew T. Hudnall; Robert B. Nadler

doi:10.1016/j.urology.2020.01.029

Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient

Minh N. Pham, Matthew T. Hudnall, Robert B. Nadler^*

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

OBJECTIVE: To describe marijuana's clinical role for urologic symptoms. METHODS: Studies related to marijuana, voiding dysfunction, lower urinary tract symptoms (LUTS), and pain through January 2019 from PubMed were evaluated for relevance and quality. RESULTS: Forty-eight studies were reviewed. Cannabinoids have mixed efficacy for neurogenic LUTS and little evidence for non-neurogenic LUTS, chronic non–cancer-related and perioperative pain. For cancer-related pain, high-level studies demonstrate cannabinoids are well-tolerated with unclear benefit. CONCLUSION: Cannabinoids appear well-tolerated in the short-term, but their efficacy and long-term impact is unproven and unknown in urologic discomfort. Cannabinoids for urologic symptoms should be further explored with well-designed randomized controlled trials.

Original language	English (US)
Pages (from-to)	8-13
Number of pages	6
Journal	Urology
Volume	139
DOIs	https://doi.org/10.1016/j.urology.2020.01.029
State	Published - May 2020

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.urology.2020.01.029

Cite this

@article{b3520c6353be46fab6091dd3129e5674,

title = "Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient",

abstract = "OBJECTIVE: To describe marijuana's clinical role for urologic symptoms. METHODS: Studies related to marijuana, voiding dysfunction, lower urinary tract symptoms (LUTS), and pain through January 2019 from PubMed were evaluated for relevance and quality. RESULTS: Forty-eight studies were reviewed. Cannabinoids have mixed efficacy for neurogenic LUTS and little evidence for non-neurogenic LUTS, chronic non–cancer-related and perioperative pain. For cancer-related pain, high-level studies demonstrate cannabinoids are well-tolerated with unclear benefit. CONCLUSION: Cannabinoids appear well-tolerated in the short-term, but their efficacy and long-term impact is unproven and unknown in urologic discomfort. Cannabinoids for urologic symptoms should be further explored with well-designed randomized controlled trials.",

author = "Pham, {Minh N.} and Hudnall, {Matthew T.} and Nadler, {Robert B.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = may,

doi = "10.1016/j.urology.2020.01.029",

language = "English (US)",

volume = "139",

pages = "8--13",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient

AU - Pham, Minh N.

AU - Hudnall, Matthew T.

AU - Nadler, Robert B.

PY - 2020/5

Y1 - 2020/5

N2 - OBJECTIVE: To describe marijuana's clinical role for urologic symptoms. METHODS: Studies related to marijuana, voiding dysfunction, lower urinary tract symptoms (LUTS), and pain through January 2019 from PubMed were evaluated for relevance and quality. RESULTS: Forty-eight studies were reviewed. Cannabinoids have mixed efficacy for neurogenic LUTS and little evidence for non-neurogenic LUTS, chronic non–cancer-related and perioperative pain. For cancer-related pain, high-level studies demonstrate cannabinoids are well-tolerated with unclear benefit. CONCLUSION: Cannabinoids appear well-tolerated in the short-term, but their efficacy and long-term impact is unproven and unknown in urologic discomfort. Cannabinoids for urologic symptoms should be further explored with well-designed randomized controlled trials.

AB - OBJECTIVE: To describe marijuana's clinical role for urologic symptoms. METHODS: Studies related to marijuana, voiding dysfunction, lower urinary tract symptoms (LUTS), and pain through January 2019 from PubMed were evaluated for relevance and quality. RESULTS: Forty-eight studies were reviewed. Cannabinoids have mixed efficacy for neurogenic LUTS and little evidence for non-neurogenic LUTS, chronic non–cancer-related and perioperative pain. For cancer-related pain, high-level studies demonstrate cannabinoids are well-tolerated with unclear benefit. CONCLUSION: Cannabinoids appear well-tolerated in the short-term, but their efficacy and long-term impact is unproven and unknown in urologic discomfort. Cannabinoids for urologic symptoms should be further explored with well-designed randomized controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=85081934277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081934277&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2020.01.029

DO - 10.1016/j.urology.2020.01.029

M3 - Review article

C2 - 32027882

AN - SCOPUS:85081934277

SN - 0090-4295

VL - 139

SP - 8

EP - 13

JO - Urology

JF - Urology

ER -

Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this